Interstitial nephritis secondary prevention: Difference between revisions
Aditya Ganti (talk | contribs) No edit summary |
|||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Interstitial nephritis}} | |||
'''Editor-In-Chief:''' [[User:C Michael Gibson|C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com <nowiki>[1]</nowiki>]; '''Associate Editor(s)-in-Chief:'''{{M.B}} | '''Editor-In-Chief:''' [[User:C Michael Gibson|C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com <nowiki>[1]</nowiki>]; '''Associate Editor(s)-in-Chief:'''{{M.B}} | ||
== Overview == | == Overview == | ||
The mainstay preventive action is to stay away from re-exposure to the offensive agents of the acute episode. Among patients with chronic inflammatory diseases such as [[Sjögren's syndrome|Sjogren's syndrome]], [[sarcoidosis]], or [[SLE]], proper control of the underlying condition alongside with consideration of offensive agent is important and should be kept in mind. | |||
== Secondary Prevention == | == Secondary Prevention == | ||
The | The mainstay preventive action is to stay away from exposure to the offensive agents of the acute episode. If the culprit drug has clearly been identified, then avoiding future use of the medication is recommended, because AIN may recur on re-exposure to the original antigen. Where known cross-reactivity exists, for example between penicillins and cephalosporins, the risk of using a related agent should be carefully weighed against the benefit of using it. If such an agent is used, the patient should be appropriately monitored for any side effects. For patients with chronic inflammatory diseases such as [[Sjögren's syndrome|Sjogren's syndrome]], [[sarcoidosis]], or [[SLE]], proper control of the underlying condition alongside with consideration of offensive agent is important. | ||
==References== | ==References== | ||
Latest revision as of 13:35, 31 July 2018
|
Interstitial nephritis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Interstitial nephritis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Interstitial nephritis secondary prevention |
|
Risk calculators and risk factors for Interstitial nephritis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:Mohsen Basiri M.D.
Overview
The mainstay preventive action is to stay away from re-exposure to the offensive agents of the acute episode. Among patients with chronic inflammatory diseases such as Sjogren's syndrome, sarcoidosis, or SLE, proper control of the underlying condition alongside with consideration of offensive agent is important and should be kept in mind.
Secondary Prevention
The mainstay preventive action is to stay away from exposure to the offensive agents of the acute episode. If the culprit drug has clearly been identified, then avoiding future use of the medication is recommended, because AIN may recur on re-exposure to the original antigen. Where known cross-reactivity exists, for example between penicillins and cephalosporins, the risk of using a related agent should be carefully weighed against the benefit of using it. If such an agent is used, the patient should be appropriately monitored for any side effects. For patients with chronic inflammatory diseases such as Sjogren's syndrome, sarcoidosis, or SLE, proper control of the underlying condition alongside with consideration of offensive agent is important.